文献速递神经肌肉病

肌萎缩侧索硬化诊断前血浆神经丝轻链水平研究

Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis.
PubMed 文献 · Neurology · 2021-10-11

该研究嵌套于3个美国前瞻性队列,纳入84例随访期间确诊ALS且有诊断前血浆样本的个体,按出生年、性别、种族、空腹状态、队列和采血时间匹配对照。结果显示诊断前5年内血浆NfL每升高1个标准差,ALS风险RR为2.68(95%CI 1.18-6.08),更早样本无显著关联;21种代谢物与诊断前NfL相关,但多重校正后均不显著。

要点

  • 诊断前5年内血浆NfL升高与ALS风险增加相关(RR 2.68,95%CI 1.18-6.08)。
  • 诊断前超过5年的样本中NfL与ALS风险无显著关联(RR 1.16,95%CI 0.78-1.73)。
  • 诊断前NfL相关代谢物在多重比较校正后均不显著。

核心结论

  • 诊断前ALS病例血浆NfL水平已升高,提示NfL可能是疾病最早阶段的有用生物标志物。

研究设计与样本

  • 嵌套于3个美国大型前瞻性队列(护士健康研究、卫生专业人员随访研究、多种族队列研究)的匹配病例对照研究,识别84例随访期间确诊ALS且有诊断前血浆样本的个体。
  • 每个病例按出生年、性别、种族/民族、空腹状态、队列和采血时间随机匹配对照。
  • 采用条件logistic回归估计ALS的率比(RR)和95%CI,校正BMI、吸烟、体力活动和尿酸水平。

主要发现

  • 诊断前5年内采集的血浆样本中,NfL每升高1个标准差与ALS风险升高相关(RR 2.68,95%CI 1.18-6.08)。
  • 诊断前更早采集的样本中,NfL每升高1个标准差与ALS风险无显著关联(RR 1.16,95%CI 0.78-1.73)。
  • ALS病例诊断前NfL水平与21种代谢物相关(p < 0.05),但多重比较校正后均不显著。

临床怎么用

  • 血浆NfL在ALS诊断前5年内已升高,可作为早期阶段候选生物标志物。
  • 诊断前更早时间点NfL与ALS风险关联不显著,解释结果时需考虑采血距诊断的时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To assess whether plasma neurofilament light chain (NfL) levels are elevated before amyotrophic lateral sclerosis (ALS) diagnosis and to evaluate whether prediagnostic NfL levels are associated with metabolic alterations. METHODS: We conducted a matched case-control study nested in 3 large prospective US cohorts (the Nurses' Health Study, the Health Professionals Follow-up Study, and the Multiethnic Cohort Study) and identified 84 individuals who developed ALS during follow-up and had available plasma samples prior to disease diagnosis. For each ALS case, we randomly selected controls from those who were alive at the time of the case diagnosis and matched on birth year, sex, race/ethnicity, fasting status, cohort, and time of blood draw. We measured NfL in the plasma samples and used conditional logistic regression to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for ALS, adjusting for body mass index, smoking, physical activity, and urate levels. RESULTS: Higher NfL levels were associated with a higher ALS risk in plasma samples collected within 5 years of the ALS diagnosis (RR per 1 SD increase 2.68, 95% CI 1.18-6.08), but not in samples collected further away from the diagnosis (RR per 1 SD increase 1.16, 95% CI 0.78-1.73). A total of 21 metabolites were correlated with prediagnostic NfL levels in ALS cases (p < 0.05), but none of these remained significant after multiple comparison adjustments. DISCUSSION: Plasma NfL levels were elevated in prediagnostic ALS cases, indicating that NfL may be a useful biomarker already in the earliest stages of the disease. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma NfL levels are elevated in prediagnostic ALS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bjornevik K, O'Reilly EJ, Molsberry S, et al. Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology. 2021. PMID: 34380747. doi:10.1212/WNL.0000000000012632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。